Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The Value of Innovation

The Value of Innovation

In 2001, the National Pharmaceutical Council provided funding for the September/October issue of Health Affairs, which focused on the value of innovation. The issue showcased a growing body of research that examines the value of pharmaceuticals and other medical innovations.

Descriptions of some of the key articles from this issue follow:

Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS

Author: Lichtenberg, FR.

This study analyzes data on prescribed medicines from the 1996 Medical Expenditure Panel Survey (MEPS), a nationally representative database on the use of health care services and spending, to examine the association between the use of newer medicines and morbidity, mortality, and health spending. According to the findings, people consuming newer drugs were significantly less likely to die by the end of the survey and were significantly less likely to experience work-loss days than were people consuming older drugs. The most notable finding, however, is that use of newer drugs tends to lower all types of nondrug medical spending, resulting in a substantial net reduction in the total cost of treating a given condition.

Is Technological Change in Medicine Worth It?

Authors: Cutler, DM; McClellan, M.

This article explores the relationship between spending and health benefits. They analyze technical change in five medical conditions to determine whether or not the benefits of medical advances exceed the costs in those diseases. In four of five conditions examined -- heart attacks, low-birthweight infants, depression, and cataracts -- benefits outweighed costs, and in the fifth condition, breast cancer, costs and benefits were equal. Putting a price on life is a difficult task, but the authors calculate that the true cost of some types of care is actually falling because of medical innovation.

Link Between Gross Profitability and Pharmaceutical R&D Spending

Authors: Scherer, FM.

This analysis focuses on the question: What does the pharmaceutical industry really do with its profits? The answer is that the new pharmaceutical discoveries benefiting consumers are being driven by the gross profit margins that pharmaceutical companies make. As profits increase, so does research and development. This ultimately yields new and promising options for consumers. In addition, the author finds that medical innovations are leading to longer life and improved quality of life.

Perspectives on the Pharmaceutical Industry

Authors: Reinhardt, UE.

This paper provides an economic perspective on the pharmaceutical industry, which has come under increasing criticism on a number of issues. Much of the criticism is based on inaccurate perceptions, and suggests that our nation can indeed afford spending on drugs that help us live longer, more productive lives. Spending on pharmaceuticals accounts for only a small fraction of our Gross Domestic Product (GDP). In fact, Americans spend more per capita on alcohol, tobacco, and entertainment combined than on pharmaceuticals.

Price of Progress: Prescription Drugs in the Health Care Market

Kleinke, JD.
Increased spending on pharmaceuticals does not explain the insurance premium increases that many consumers are seeing. The author points out that pharmaceuticals are a small fraction of the total equation, and that even though spending on pharmaceuticals is increasing, that rise in expenditures amounts to a small percentage of the premium increases.

Blog Post

Bundled Payments: Opportunities and Challenges

As use of bundled payments increases, how do health system stakeholders minimize the risk of unintended consequences and maximize chances this...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Press Release

New Study Examines Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers

(Washington, DC, September 16, 2015)—A newly released study has found that risk-sharing agreements (RSAs) between pharmaceutical companies and health...
Press Release

Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management

Washington, D.C. (December 4, 2014)—A case study published in the December 2014 issue of the Journal of Managed Care & Specialty Pharmacy...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
Commentary and Testimony Page

High Stakes for Setting Research Standards

What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
YouTube Videos

Consumer-Directed Health Plans

A unique survey of large employers sheds light on the strategies and best practices that they follow when designing and implementing consumer-...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
YouTube Videos

Engaging Consumers in Today's Changing Health Care Payment and Delivery Environment

The current health care delivery system is evolving from a fee-for-service system to one that is performance-based. How does this shift impact...
YouTube Videos

Rapid-Learning Health Care Systems, Explained

Dr. Lucy Savitz, director of research and education, Institute for Healthcare Delivery Research, Intermountain Healthcare, explains rapid learning...
Blog Post

Bundled Payments: Opportunities and Challenges

As use of bundled payments increases, how do health system stakeholders minimize the risk of unintended consequences and maximize chances this...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...

What Contributes Most to High Health Care Costs?

A small segment of the population—often the sickest

The Myth of Average: Why Individual Patient Differences Matter

Within today’s health care environment, so much of t

  •  
  • 1 of 46
  • >